% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bakas:1032187,
author = {Bakas, Spyridon and Vollmuth, Philipp and Galldiks, Norbert
and Booth, Thomas C and Aerts, Hugo J W L and Bi, Wenya
Linda and Wiestler, Benedikt and Tiwari, Pallavi and Pati,
Sarthak and Baid, Ujjwal and Calabrese, Evan and Lohmann,
Philipp and Nowosielski, Martha and Jain, Rajan and Colen,
Rivka and Ismail, Marwa and Rasool, Ghulam and Lupo, Janine
M and Akbari, Hamed and Tonn, Joerg C and Macdonald, David
and Vogelbaum, Michael and Chang, Susan M and Davatzikos,
Christos and Villanueva-Meyer, Javier E and Huang, Raymond
Y},
title = {{A}rtificial {I}ntelligence for {R}esponse {A}ssessment in
{N}euro {O}ncology ({AI}-{RANO}), part 2: recommendations
for standardisation, validation, and good clinical practice},
journal = {The lancet / Oncology},
volume = {25},
number = {11},
issn = {1470-2045},
address = {London},
publisher = {The Lancet Publ. Group},
reportid = {FZJ-2024-06056},
pages = {e589 - e601},
year = {2024},
abstract = {Technological advancements have enabled the extended
investigation, development, and application of computational
approaches in various domains, including health care. A
burgeoning number of diagnostic, predictive, prognostic, and
monitoring biomarkers are continuously being explored to
improve clinical decision making in neuro-oncology. These
advancements describe the increasing incorporation of
artificial intelligence (AI) algorithms, including the use
of radiomics. However, the broad applicability and clinical
translation of AI are restricted by concerns about
generalisability, reproducibility, scalability, and
validation. This Policy Review intends to serve as the
leading resource of recommendations for the standardisation
and good clinical practice of AI approaches in health care,
particularly in neuro-oncology. To this end, we investigate
the repeatability, reproducibility, and stability of AI in
response assessment in neuro-oncology in studies on factors
affecting such computational approaches, and in publicly
available open-source data and computational software tools
facilitating these goals. The pathway for standardisation
and validation of these approaches is discussed with the
view of trustworthy AI enabling the next generation of
clinical trials. We conclude with an outlook on the future
of AI-enabled neuro-oncology.},
cin = {INM-4 / INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-3-20090406},
pnm = {5253 - Neuroimaging (POF4-525) / 5252 - Brain Dysfunction
and Plasticity (POF4-525)},
pid = {G:(DE-HGF)POF4-5253 / G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
pubmed = {39481415},
UT = {WOS:001348280600001},
doi = {10.1016/S1470-2045(24)00315-2},
url = {https://juser.fz-juelich.de/record/1032187},
}